Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe

Clinical Toxicology

Volumn 52, Issue 5, 2014, Pages 561-565

  Tang, M H Y ^a   Ching, C K ^a   Tsui, M S H ^b   Chu, F K C ^c   Mak, T W L ^a  

^a PRINCESS MARGARET HOSPITAL   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Novel psychoactive substance; Phenethylamine; Serotonergic; Sympathomimetic; Toxicity

Indexed keywords

25B NBOME; 25C NBOME; DIAZEPAM; LORAZEPAM; PHENETHYLAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGITATION; ARTICLE; CASE REPORT; CONFUSION; HUMAN; HYPERTENSION; HYPERTHERMIA; INTOXICATION; LIVER FUNCTION TEST; MALE; MYDRIASIS; RHABDOMYOLYSIS; SUBSTANCE ABUSE; SWEATING; TACHYCARDIA; TANDEM MASS SPECTROMETRY; URINALYSIS;

NOVEL PSYCHOACTIVE SUBSTANCE; PHENETHYLAMINE; SEROTONERGIC; SYMPATHOMIMETIC; TOXICITY;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; ADULT; CHROMATOGRAPHY, LIQUID; HALLUCINOGENS; HUMANS; MALE; PHENETHYLAMINES; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEVERITY OF ILLNESS INDEX; SOLID PHASE EXTRACTION; STREET DRUGS; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY;

EID: 84902249627     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2014.909932     Document Type: Article

References (22)

1. Davis GG. Drug abuse: newly-emerging drugs and trends. Clin Lab Med 2012;32:407-414.
2. Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse. Emerg Med Clin North Am 2014;32:1-28.
3. Shulgin A, Shulgin A. PIHKAL: A Chemical Love Story. Berkeley, CA: Transform Press;2011.
4. Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM. 2C or not 2C: phenethylamine designer drug review. J Med Toxicol 2013;9:172-178.
5. Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila) 2011;49:705-719.
6. Curtis B, Kemp P, Harty L, Choi C, Christensen D. Postmortem identification and quantitation of 2,5-dimethoxy-4-n-propylthiophenethylamine using GC-MSD and GC-NPD. J Anal Toxicol 2003;27:493-498.
7. Miyajima M, Matsumoto T, Ito S. 2C-T-4 intoxication: acute psychosis caused by a designer drug. Psychiatry Clin Neurosci 2008;62:243.
8. Topeff JM, Ellsworth H, Willhite LA, Bangh SA, Edwards EM, Cole JB. A case series of symptomatic patients including one fatality following 2C-E exposure. Clin Toxicol (Phila) 2011;40:526.
9. Hill SL, Doris T, Gurung S, Katebe S, Lomas A, Dunn M, et al. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin Toxicol (Phila) 2013;51:487-492.
10. Poklis JL, Nanco CR, Troendle MM, Wolf CE, Poklis A. Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal 2013;doi:10.1002/dta.1522.
11. Zuba D, Sekula K, Buczek A. 25C-NBOMe-new potent hallucinogenic substance identified on the drug market. Forensic Sci Int 2013;227:7-14.
12. Braden MR, Parrish JC, Naylor JC, Nichols DE. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol 2006;70:1956-1964.
13. Lobos M, Borges Y, Gonzalez E, Cassels BK. The action of the psychoactive drug 2C-B on isolated rat thoracic aorta. Gen Pharmacol 1992;23:1139-1142.
14. Saez P, Borges Y, Gonzalez E, Cassels BK. Alpha-adrenergic and 5-HT2-serotonergic effects of some beta-phenylethylamines on isolated rat thoracic aorta. Gen Pharmacol 1994;25:211-216.
15. Kelly A, Eisenga B, Riley B, Judge B. Case series of 25I-NBOMe exposures with laboratory confirmation. Clin Toxicol (Phila) 2012;50:702.
16. Poklis JL, Charles J, Wolf CE, Poklis A. High-performance liquid chromatography tandem mass spectrometry method for the determination of 2CC-NBOMe and 25I-NBOMe in human serum. Biomed Chromatogr 2013;27:1794-1800.
17. Poklis JL, Devers KG, Arbefeville EF, Pearson JM, Houston E, Poklis A. Postmortem detection of 25I-NBOMe [2-(4-iodo-2, 5-dimethoxyphenyl)-N-[(2- methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int 2013;doi:10.1016/j.forsciint.2013.10.015.
18. Rose RS, Cumpston KL, Stromberg PE, Wills BK. Severe poisoning following self-reported use of 25I, a novel substituted amphetamine. Clin Toxicol (Phila) 2012;50:707.
19. Rose SR, Poklis JL, Poklis A. A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin Toxicol (Phila) 2013;51:174-177.
20. Sporkert F, Augsburger M, Vilarino R, Michaud K, Schlapfer M, Marcourt L. Identification and implication of the phenethylamine derivative 25B-NBOMe in a case of an unresolved fatality. 51st Annual Meeting of the International Association of Forensic Toxicologists; 2013.
21. Stellpflug SJ, Kealey SE, Hegarty CB, Janis GC. 2-(4-Iodo-2, 5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25INBOMe): clinical case with unique confirmatory testing. J Med Toxicol 2013;doi:10.1007/s13181- 013-0314-y.
22. Drug Enforcement Administration. Department of Justice. Schedules of controlled substances: temporary placement of three synthetic phenethylamines into Schedule I. Final order. Fed Regist 2013;78:68716-68719.